ZTS - Zoetis Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
110.33
-0.46 (-0.42%)
As of 2:35PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close110.79
Open110.96
Bid110.44 x 900
Ask110.47 x 800
Day's Range110.04 - 111.25
52 Week Range78.90 - 112.25
Volume551,660
Avg. Volume2,003,392
Market Cap52.81B
Beta (3Y Monthly)0.63
PE Ratio (TTM)38.58
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.66 (0.65%)
Ex-Dividend Date2019-07-18
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire19 days ago

    Zoetis to Participate in the William Blair 39th Annual Growth Stock Conference

    Zoetis Inc. (ZTS) will participate in the William Blair 39th Annual Growth Stock Conference on Thursday, June 6, 2019, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines, medicines and diagnostics, which are complemented by genetic tests, biodevices and a range of services.

  • Business Wire28 days ago

    Zoetis to Participate in the Stifel 2019 Dental & Veterinary Conference

    Zoetis Inc. (ZTS) will participate in the Stifel 2019 Dental & Veterinary Conference on Wednesday, May 29, 2019, in New York, N.Y. Clint Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics will represent the company and respond to questions from analysts.

  • Business Wirelast month

    Zoetis Announces Results of Its Annual Meeting of Shareholders; Board Declares Third Quarter 2019 Dividend

    Zoetis held its annual meeting today in Short Hills, N.J., with Chairman Michael B. McCallister presiding over the business portion of the meeting and shareholder voting. Chief Executive Officer Juan Ramón Alaix discussed the company’s strong performance in 2018 and its strategies for continued growth and market leadership in the global animal health industry. Juan Ramón Alaix, Paul M. Bisaro, Frank A. D’Amelio and Michael B. McCallister have been elected as directors for three-year terms.

  • Business Wire2 months ago

    Zoetis Announces First Quarter 2019 Results

    Zoetis $ZTS reports first quarter 2019 financial results.

  • Business Wire2 months ago

    Forbes Names Zoetis One of America’s Best Employers for Fourth Year in a Row

    “At Zoetis, we know our people shape our reputation as a great place to work and drive our success,” said Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications. Forbes determined its America’s Best Employers list based on an independent survey among a sample of 50,000 American employees working for companies with at least 1,000 people in their U.S. operations.

  • Business Wire3 months ago

    Zoetis to Host Webcast and Conference Call on First Quarter 2019 Financial Results

    Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review first quarter 2019 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses.

  • Business Wire3 months ago

    Zoetis Named a Top Company for Executive Women by NAFE

    This is the first year that Zoetis has earned a spot on this prestigious list. “We are honored to be named one of NAFE’s Top Companies for Executive Women for the first time,” said Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications at Zoetis.

  • Business Wire4 months ago

    Zoetis Reports Fourth Quarter and Full Year 2018 Results

    Zoetis $ZTS announces Q4 and full year 2018 financial results

  • Business Wire4 months ago

    Zoetis Declares Second Quarter 2019 Dividend

    Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future use of cash and dividend payments, and other future events.

  • GlobeNewswire5 months ago

    Detailed Research: Economic Perspectives on Pitney Bowes, Zoetis, Rent-A-Center, Live Nation Entertainment, Everbridge, and KB Home — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire6 months ago

    Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2018 Financial Results

    Zoetis Inc. will host a webcast and conference call at 8:30 a.m. on Thursday, Feb. 14, 2019. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review fourth quarter and full year 2018 financial results and respond to questions from financial analysts during the call.

  • Business Wire6 months ago

    Zoetis to Participate in the 37th Annual J.P. Morgan Healthcare Conference

    Zoetis Inc. (ZTS) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco, Calif. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets medicines, vaccines, and diagnostic products, which are complemented by biodevices, genetic tests and a range of services.

  • Business Wire6 months ago

    Zoetis Announces Authorization of $2 Billion Share Repurchase Program

    Zoetis Inc. (ZTS) today announced that its Board of Directors has authorized a $2 billion multi-year share repurchase program as part of its long-term capital allocation plans. The company’s previous $1.5 billion share repurchase program, which was approved in December 2016, is expected to be completed in the first half of next year. The Board of Directors also declared a first quarter 2019 dividend of $0.164 per share, an increase of 30% from the quarterly dividend rate paid in 2018.

  • Business Wire7 months ago

    Zoetis Announces Third Quarter 2018 Results

    Zoetis $ZTS reports Q3'18 financial results.

  • Business Wire8 months ago

    Zoetis to Participate in the Credit Suisse 27th Annual Healthcare Conference

    Zoetis Inc. (ZTS) will participate in the Credit Suisse 27th Annual Healthcare Conference on Tuesday, Nov. 13, 2018, in Scottsdale, Ariz. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services.

  • GlobeNewswire8 months ago

    New Research Coverage Highlights Zoetis, TripAdvisor, The Gap, Unit, WestRock, and Verastem — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire8 months ago

    Zoetis Declares Fourth Quarter 2018 Dividend

    Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future use of cash and dividend payments, and other future events.

  • Business Wire9 months ago

    Zoetis to Host Webcast and Conference Call on Third Quarter 2018 Financial Results

    Zoetis Inc. will host a webcast and conference call at 8:30 a.m. on Thursday, Nov. 1, 2018. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review third quarter 2018 financial results and respond to questions from financial analysts during the call.

  • Business Wire9 months ago

    Zoetis Named a Top Company for Working Mothers

    Zoetis named one of Working Mother Magazine's 100 Best Companies for the fifth year in a row. #WM100Best

  • Business Wire9 months ago

    Zoetis to Participate in the 2018 Cantor Global Healthcare Conference

    Zoetis Inc. (ZTS) will participate in the 2018 Cantor Global Healthcare Conference on Monday, Oct. 1, 2018, in New York, N.Y. Clint Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Genetics and Aquatic Health, will represent the company and respond to questions from analysts. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services.

  • Business Wire10 months ago

    Zoetis Announces Pricing of $1.5 Billion of Senior Notes

    Zoetis Inc. (ZTS) today announced that it has agreed to sell $1.5 billion of senior notes, consisting of $300 million aggregate principal amount of floating rate senior notes due 2021, $300 million aggregate principal amount of 3.250% senior notes due 2021, $500 million aggregate principal amount of 3.900% senior notes due 2028 and $400 million aggregate principal amount of 4.450% senior notes due 2048, in an underwritten public offering. Zoetis intends to use the net proceeds to repay $500 million drawn under the 364-day revolving credit facility entered into on July 27, 2018, repay $500 million issued under its commercial paper program, and for general corporate purposes. Barclays Capital Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and MUFG Securities Americas Inc. are acting as joint book-running managers of the underwriters.

  • Business Wire10 months ago

    Zoetis Announces Second Quarter 2018 Results

    Zoetis $ZTS reports 2Q18 financial results.

  • PR Newswire11 months ago

    Triumph Bancorp Set to Join S&P SmallCap 600

    NEW YORK , July 31, 2018 /PRNewswire/ -- Triumph Bancorp Inc. (NASD: TBK) will replace Abaxis Inc. (NASD: ABAX) in the S&P SmallCap 600 effective prior to the open of trading on Monday, August 6 . S&P ...

  • Business Wire11 months ago

    Zoetis Completes Acquisition of Abaxis, a Leading Global Provider of Veterinary Point-of-Care Diagnostic Instruments

    Zoetis Inc. (ZTS) today announced the completion of the acquisition of Abaxis, a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care services for US $83 per share in cash, or approximately $2.0 billion in aggregate. The acquisition, which was first announced on May 16, follows the satisfaction of all conditions to the closing, including the receipt of the approval of the acquisition by Abaxis shareholders at a shareholder meeting earlier today.

  • ACCESSWIRE11 months ago

    Wired News - Zoetis Announces HSR Clearance for Acquisition of Animal Health Company Abaxis

    LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want access to our free research report on Zoetis Inc. (NYSE: ZTS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZTS as the Company's latest news hit the wire. On July 06, 2018, the Company announced that it has completed the acquisition of Abaxis, Inc. (NASDAQ: ABAX), which is a leader in the development, manufacture, and marketing of diagnostic instruments for veterinary point-of-care services, for $83.00 per share in cash, or approximately $2.0 billion in total.